hormones researchIs TRT Bad for Your Heart? What the 2026 Evidence Finally Confirms
The TRAVERSE trial (5,246 men) and the 2026 European Expert Panel position statement settle the cardiovascular debate around TRT. Here's what the data actually shows.
For more than two decades, testosterone-replacement therapy carried a shadow the data never quite supported: an FDA black-box warning suggesting it raised the risk of heart attack and stroke, added in 2015 based on small, methodologically weak studies. That warning shaped how physicians prescribed, how patients perceived risk, and — critically — how many men with genuine hypogonadism went untreated.
The TRAVERSE trial changed that in 2023. The European Expert Panel's position statement, published in 2026, closed the argument. What the data now says is precise, and it differs substantially from what most men — and many clinicians — still believe.
What TRAVERSE Actually Found (and What It Didn't)
The TRAVERSE trial enrolled 5,246 men aged 45 to 80 with confirmed hypogonadism and either pre-existing cardiovascular disease or a high 10-year cardiovascular risk score. This was not a low-risk population. These were the men the FDA warning was written to protect.
Over a mean follow-up of 27 months, men randomized to daily transdermal testosterone gel showed no significant increase in major adverse cardiovascular events — the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The trial met its noninferiority threshold. Testosterone was not worse than placebo for the cardiac events that matter most.
This point deserves emphasis, because noninferiority trials are routinely misread. Noninferior does not mean equivalent in every direction. It means the therapy does not materially worsen the specific outcome measured — MACE — compared to placebo. TRAVERSE confirmed this for 5,246 high-risk men across 27 months. That is a stronger statement than any prior study had been able to make.
One secondary signal did emerge: a higher incidence of nonfatal atrial fibrillation in the testosterone arm, with an absolute difference of approximately 1%. This is the finding that TRT critics have amplified since 2023. Its interpretation requires care — and context — which most commentary has not provided.
The European Expert Panel's 2026 Verdict
The 2026 position statement from the European Expert Panel for Testosterone Research, published in Andrology, synthesized TRAVERSE alongside multiple prior meta-analyses and arrived at a formal clinical consensus: testosterone therapy does not significantly increase MACE risk in appropriately selected hypogonadal men.
The Expert Panel explicitly addressed the prior FDA black-box warning. Their conclusion: that warning was based on observational data and short-duration studies with high heterogeneity — not on RCT evidence of the scale or design quality that TRAVERSE now provides. The black-box cardiovascular warning has been effectively nullified by the evidence base as it stands in 2026.
Two conditions define appropriate selection in the Expert Panel's framing:
First, biochemically confirmed hypogonadism — two separate morning blood tests on different days showing total testosterone consistently below the clinical threshold (~300 ng/dL in most guidelines), combined with clinical symptoms. Symptoms without confirmed biochemistry are not sufficient to diagnose hypogonadism or justify TRT.
Second, absence of acute cardiac instability. TRT is contraindicated within 90 days of a myocardial infarction or stroke. Outside this exclusion window, stable cardiovascular disease — including the population enrolled in TRAVERSE — does not automatically disqualify men from treatment consideration.
The Atrial Fibrillation Signal: Genuine but Contested
The TRAVERSE atrial fibrillation finding is the most debated secondary result in testosterone research. It deserves an honest treatment rather than dismissal or catastrophizing.
Within TRAVERSE specifically, the AF rate was higher in the testosterone arm than placebo, with an absolute difference around 1%. The mechanism is plausible: testosterone stimulates erythropoiesis and may affect electrophysiology and autonomic tone in ways that could lower the atrial fibrillation threshold, particularly at higher hematocrit levels.
However, when TRAVERSE is pooled with the 105 other placebo-controlled RCTs in a 2024 meta-analytic update published in Expert Opinion on Drug Safety, the aggregate atrial fibrillation signal disappears. This tells you something clinically important: the AF risk, if real, is not a universal property of testosterone at therapeutic doses — it likely depends on baseline patient characteristics, hematocrit trajectory, or dosing approach specific to the TRAVERSE population.
The practical implication is not that AF risk should be ignored. It is that the AF question is now a monitoring question, not a contraindication question. Men on TRT with known AF or with strong AF risk factors (obesity, alcohol use, sleep apnea, structural heart disease) warrant ECG surveillance. For a man with no AF risk factors and normal hematocrit, the AF finding from TRAVERSE does not change the benefit-risk calculation substantially.
Why Hematocrit Is the Actual Deal-Breaker
The cardiovascular risk profile of TRT is dominated not by MACE or AF but by secondary polycythemia — the dose-dependent increase in red blood cell mass that testosterone stimulates through erythropoietin upregulation.
A 2026 analysis of men on TRT (PMC12721636) confirmed what clinical intuition and smaller studies had long suggested: men whose hematocrit reaches or exceeds 52% during the first year of therapy face meaningfully elevated risk of both major adverse cardiovascular events and venous thromboembolism. The mechanism is straightforward — elevated hematocrit increases blood viscosity, elevating thrombotic risk in both arterial and venous beds.
In the real-world UK cohort of 9,537 men (median age 42), published in the World Journal of Men's Health in 2026, only 3.24% of patients reached hematocrit above 0.54 when treated in a properly monitored clinical setting. This is the kind of outcome that responsible TRT management produces: the vast majority of patients stay within the safe range when monitoring is functioning correctly.
The clinical lesson is precise: hematocrit elevation is not a reason to avoid TRT. It is a reason to monitor it rigorously and dose-adjust when indicated.
Current guidance specifies:
- Baseline hematocrit before initiation
- Recheck at 3 months after starting treatment
- Ongoing monitoring every 6–12 months once stable
- Dose reduction or therapy interruption if hematocrit exceeds 54%
The cardiovascular debate around TRT is settled. TRAVERSE and the 2026 European Expert Panel have answered the question. What remains is applying those findings with precision: right patient, right diagnosis, right monitoring.
Who Should and Shouldn't Be on TRT
The 2026 Endocrine Society statement — published July 16, following an FDA expert panel review of testosterone eligibility criteria in December 2025 — reaffirms what the European guidelines had also established: the diagnosis of hypogonadism is the gating requirement, and that diagnosis has specific biochemical standards that symptoms alone cannot satisfy.
To be diagnosed with hypogonadism, a man needs:
- Symptoms consistent with testosterone deficiency — low libido, fatigue, loss of muscle mass, depressed mood, erectile dysfunction, reduced bone density
- Two separate morning total testosterone measurements (drawn before 10 AM) below the clinical threshold on different days
Both conditions must be met. The symptom overlap between hypogonadism and normal aging, burnout, obesity, and sleep deprivation is substantial. A man with these symptoms who draws blood at 4 PM after a poor night's sleep and gets a total testosterone of 285 ng/dL does not yet have a diagnosis — he has one data point.
Men for whom TRT is not appropriate:
- Those who want fertility preservation (TRT suppresses LH/FSH, which suppresses sperm production; gonadotropin-based protocols are the alternative)
- Those within 90 days of MI or stroke
- Those with untreated prostate cancer (though data does not support TRT causing prostate cancer in men without it)
- Those with elevated baseline hematocrit (above 50%) before treatment starts
Men in the target PrimalPrime demographic — high-performing men in their mid-30s to mid-40s with confirmed biochemical hypogonadism — represent exactly the population where TRT's benefit-risk profile is most favorable. The real-world UK cohort had a median age of 42 and showed meaningful improvements in libido, energy, mood, erection quality, physical performance, and work output across all eight measured quality-of-life domains. At 3.24% exceeding the hematocrit safety threshold, the monitored complication rate was low.
Before reaching for TRT, it is worth establishing whether testosterone is genuinely low biochemically, and whether upstream drivers — sleep, training load, body composition, alcohol intake, stress — have been addressed. The natural optimization case is not trivial: poor sleep alone can suppress total testosterone by 10–15% in under a week. Correcting sleep, body composition, and training approach before rechecking is standard protocol for any serious evaluation.
The Protocol
Step 1 — Get a proper baseline
Before any clinical evaluation, optimize the controllable variables for 4–8 weeks: consistent 7.5–8 hours of sleep, reduce alcohol, manage training load to avoid overtraining syndrome, and assess body composition. Then schedule morning blood draws (before 10 AM) on two separate days measuring total testosterone, free testosterone (ideally calculated from SHBG), LH, FSH, hematocrit, hemoglobin, PSA, liver enzymes, and lipid panel.
Step 2 — Confirm the diagnosis, not just the symptom list
If both blood tests confirm total testosterone below ~300 ng/dL (or free testosterone below ~65 pg/mL) alongside clinical symptoms, the biochemical diagnosis is met. If only one test is low, repeat before proceeding. If testosterone is in the low-normal range (300–400 ng/dL) with significant symptoms, free testosterone and SHBG should be examined carefully — high SHBG can mask functional hypogonadism at normal total T.
Step 3 — Choose the delivery method
Daily transdermal gel (as used in TRAVERSE) produces stable levels and avoids the peak-trough variability of injections. Testosterone cypionate or enanthate (weekly or biweekly IM/SQ injections) achieves higher peak levels and is preferred by men who want tighter dosing control. Pellet implants provide 3–6 month release but cannot be adjusted if side effects emerge. Start conservatively — the goal is mid-normal physiological levels (500–700 ng/dL total T), not supraphysiological.
Step 4 — Monitor with structure
- Hematocrit: check at 3 months, then every 6 months. Dose adjust if approaching 52%, discontinue temporarily if exceeding 54%.
- Total and free testosterone: check at 3 months to confirm therapeutic range; annually once stable.
- PSA: annually in men over 40.
- Symptoms: reassess at 3 months. If no meaningful improvement across multiple domains by 6 months at adequate levels, revisit the diagnosis.
Step 5 — Track what matters
Use concrete outcome metrics, not just blood values. The real-world cohort data shows improvements across libido, energy, erection quality, mood, physical strength, and work performance. If these are not moving after 3–6 months at confirmed therapeutic levels, consider secondary factors — sleep quality, HRV, cortisol, thyroid — before escalating dose.
Know where your testosterone actually stands? → Explore the testosterone biomarker page for reference ranges by age, optimal targets, and what drives T levels in both directions. Or run the PrimalPrime Testosterone Score to get a full picture before deciding next steps.